Go Deep
Hester Biosciences Limited
Hester Biosciences Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,651 | 12.8 | 5.09 | 0.53 | 2,154.30 |
Hester Biosciences Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 772,440,000.0 | 1,001,100,000.0 | 774,150,000.0 | 709,690,000.0 |
| Net Profit | 969,810,000.0 | 159,820,000.0 | 87,650,000.0 | 144,490,000.0 |
| EPS | 113.7 | 19.4 | 10.9 | 16.9 |
Hester Biosciences Limited Revenue & Profit: Last 4 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 3,325,990,000.0 | 3,111,020,000.0 | 3,045,460,000.0 | 2,660,910,000.0 |
| Net Profit | 556,390,000.0 | 274,880,000.0 | 188,890,000.0 | 266,270,000.0 |
| EPS | 65.4 | 32.3 | 22.2 | 31.3 |
Hester Biosciences Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 6,779,410,000.0 | 6,533,850,000.0 | 6,623,470,000.0 | 6,699,660,000.0 | — |
| Total Liabilities | 3,101,520,000.0 | 3,267,290,000.0 | 3,594,720,000.0 | 3,814,200,000.0 | — |
| Total Equity | 3,602,350,000.0 | 3,142,550,000.0 | 2,917,930,000.0 | 2,797,300,000.0 | — |
Owes vs Owns
Hester Biosciences Limited owed ₹0.46 for every ₹1 it owned in Mar 2026, down from ₹0.57 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.46× | 0.50× | 0.54× | 0.57× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Hester Biosciences Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Receivables 14.1%Inventory 10.7%Fixed assets (tangible) 61.0%Intangible assets 1.4%Long-term investments 6.3%Other assets 6.1%
How it's funded — Mar 2026
Short-term debt 14.5%Long-term debt 13.3%Payables 3.6%Other liabilities 14.3%Shareholders' equity 54.3%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 2.9 | 6.5 | 13.0 | 13.8 |
| Receivables | 95.4 | 73.2 | 78.6 | 79.6 |
| Inventory | 72.5 | 70.4 | 75.6 | 84.8 |
| Fixed assets (tangible) | 413.6 | 410.9 | 409.6 | 409.1 |
| Intangible assets | 9.7 | 6.7 | 3.9 | 2.9 |
| Long-term investments | 42.6 | 34.1 | 29.9 | 25.3 |
| Other assets | 41.2 | 51.6 | 51.7 | 54.4 |
| Liabilities & equity | ||||
| Short-term debt | 98.3 | 74.4 | 56.9 | 83.2 |
| Long-term debt | 90.0 | 133.4 | 182.1 | 184.8 |
| Payables | 24.7 | 29.4 | 25.9 | 30.0 |
| Other liabilities | 97.2 | 89.5 | 94.6 | 83.5 |
| Shareholders' equity | 367.8 | 326.7 | 302.9 | 288.5 |
| Net tangible assets | 350.5 | 307.6 | 287.9 | 276.8 |
Hester Biosciences Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 641,410,000.0 | 645,110,000.0 | 481,830,000.0 | 235,960,000.0 | — |
| Investing Activities | -28,690,000.0 | -190,030,000.0 | -226,060,000.0 | -769,990,000.0 | — |
| Financing Activities | -487,940,000.0 | -517,170,000.0 | -260,930,000.0 | 417,580,000.0 | — |